MOTS-c: the mitochondrial-derived peptide in recent research
- Revexa | Research Peptides
- 3 hours ago
- 2 min read
Research summary. Everything below describes published research on MOTS-c as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption.
MOTS-c is unusual, it is a peptide your own mitochondria encode, and it sits at the centre of metabolic and mitochondrial research. It works largely through AMPK, the same cellular energy pathway that exercise activates, which is why it is often described as an "exercise-mimetic" in the literature. Two 2026 studies added to the picture.
Muscle in a wasting model
In a tumour-bearing mouse model of cachexia (severe muscle wasting), researchers reported that MOTS-c did not stop overall weight loss but partially preserved skeletal muscle (Frontiers in Medicine, May 2026). Cell experiments showed raised PGC-1-alpha and AMPK signalling and suppression of muscle-breakdown genes (atrogin-1, MuRF1). The researchers were careful to describe the protection as partial.
Source: Frontiers in Medicine, May 2026
A possible biomarker angle
A separate cross-sectional human study of 90 Hashimoto's thyroiditis patients versus 90 matched controls found circulating MOTS-c was significantly lower in the patient group, and lower levels tracked inversely with BMI, glucose measures and immune markers (Journal of Clinical Medicine, May 2026). This is an association study, positioning the peptide as a candidate biomarker rather than a treatment.
The compound at Revexa
Related mitochondrial-research compounds include SS-31 (Elamipretide) and NAD+.
All products at Revexa are supplied strictly for laboratory and research use only. Not for human or veterinary use, and not for consumption. The research described above is reported as published, in the models the original authors studied, and must not be read as a claim, benefit or instruction for any individual.
Comments